Entrada Therapeutics (TRDA) Common Equity (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Common Equity of $270.9 million for Q1 2026, down 35.09% year-over-year from $417.3 million in Q1 2025, and down 11.52% quarter-over-quarter from $306.1 million in Q4 2025.
Entrada Therapeutics (TRDA) Common Equity (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $270.9 million for Q1 2026.
- In Q1 2026, Common Equity fell 35.09% year-over-year to $270.9 million; the TTM figure through Mar 2026 stood at $270.9 million (down 35.09% YoY), while the FY2025 annual figure was $306.1 million, down 28.59% from the prior year.
- Common Equity for Q1 2026 stood at $270.9 million, down from $306.1 million in the prior quarter.
- The five-year high for Common Equity was $429.9 million in Q2 2024, with the low at $206.9 million in Q2 2023.
- The 5-year median for Common Equity is $270.9 million (2026), against an average of $304.1 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity surged 658.48% in 2022, then sank 35.09% in 2026.
- Entrada Therapeutics' Common Equity stood at $212.6 million in 2022, then grew by 14.02% to $242.4 million in 2023, then soared by 76.88% to $428.7 million in 2024, then retreated by 28.59% to $306.1 million in 2025, then decreased by 11.52% to $270.9 million in 2026.
- Business Quant data shows TRDA's Common Equity at $270.9 million in Q1 2026, $306.1 million in Q4 2025, and $340.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 233.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233.41 Mn |
| Mar 31, 2026 | 270.85 Mn |
| Dec 31, 2025 | 306.13 Mn |
| Sep 30, 2025 | 340.72 Mn |
| Jun 30, 2025 | 379.51 Mn |
| Mar 31, 2025 | 417.26 Mn |
| Dec 31, 2024 | 428.68 Mn |
| Sep 30, 2024 | 422.45 Mn |
| Jun 30, 2024 | 429.93 Mn |
| Mar 31, 2024 | 269.37 Mn |
| Dec 31, 2023 | 242.36 Mn |
| Sep 30, 2023 | 246.66 Mn |
| Jun 30, 2023 | 206.91 Mn |
| Mar 31, 2023 | 229.61 Mn |
| Dec 31, 2022 | 212.55 Mn |
| Sep 30, 2022 | 233.22 Mn |
| Jun 30, 2022 | 256.04 Mn |
| Mar 31, 2022 | 277.39 Mn |
| Dec 31, 2021 | 298.72 Mn |
| Sep 30, 2021 | -72.59 Mn |